Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · PALVELLA THERAPEUTICS, INC. (PVLA)

Palvella Q2 net loss widens to $21.9 million as NDA submission begins

Negative Impact 3 of 5 earnings Written later

Palvella Therapeutics reported a second-quarter 2026 net loss of $21.9 million, or $1.52 per share, up from $9.5 million, or $0.86 per share, a year earlier. The company said it submitted the first module of its rolling NDA for QTORIN rapamycin in microcystic lymphatic malformations and ended the quarter with $250.6 million in cash, cash equivalents and short-term investments.

Key points

  • Net loss for the three months ended June 30, 2026 was $21.9 million, or $1.52 per share, versus $9.5 million, or $0.86 per share, a year earlier.
  • Research and development expenses rose to $12.5 million from $5.1 million; general and administrative expenses rose to $8.9 million from $4.1 million.
  • Cash, cash equivalents and short-term investments were $250.6 million as of June 30, 2026.
  • The company expects to complete the NDA submission in the second half of 2026 and plans a standalone U.S. launch in the first half of 2027, if approved.

The filing

CompanyPALVELLA THERAPEUTICS, INC. (PVLA)
Form8-K, current report
Filed with the SECAug 4, 2026, 7:30 AM ET
Accession number0001193125-26-331556

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.